Bio-Techne Corporation launched new DNAscope Assays and expanded the RNAscope technology which is an advanced in situ hybridization (ISH) assay to allow for the quick and versatile creation of probes for any DNA target, as well as the visualization of targets in formalin-fixed paraffin-embedded (FFPE) tissues. Furthermore, DNAscope offers advantages over current commercial FISH methods and permits scientists to see and count gene copy number changes and gene rearrangements/fusions in tissues with spatial and morphological contexts.
Leica Biosystems Nussloch GmbH together with Bio-Techne introduced the CE-IVD marked RNAscope In Situ Hybridization Detection Kit to assist pathologists in gaining access to the top software to help their diagnostics labs and allow greater target sensitivity and specificity compared to conventional ISH techniques.
Author Credits: Radhika Gupta, Shivam Bhutani
Report ID: 5338
Published Date: Oct 20, 2023
Report Format: PDF, PPT
Frequently Asked Questions (FAQ)
The rising incidence of cancer across the globe and the growing technological advancements in In-vitro diagnostics (IVD) are the major factors driving the growth of the market.
The market size of In Situ Hybridization is anticipated to attain a CAGR of 12% over the forecast period, i.e., 2024 â€“ 2036.
The major players in the market are Thermo Fisher Scientific Inc., Abbott, PerkinElmer, Inc., Leica Biosystems Nussloch GmbH, F. Hoffman-La Roche Limited, NeoGenomics Laboratories, Inc., Advanced Cell Diagnostics, Inc., BioView, Agilent Technologies, Inc., Merck KGaA, Bio-Rad Laboratories, Inc., Oxford Gene Technology IP Limited, and others.
The fluorescent In situ hybridization (FISH) segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.
The market in the North American region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.